China’s National Medical Products Administration, the main regulatory body in the sector, has approved the commercialization and use of the Cuban humanized monoclonal antibody Nimotuzumab for the treatment of pancreatic cancer. The decision is based on positive results from clinical studies, the drug’s efficacy in inhibiting the growth of malignant cells, and its successful use since 1998 in Cuba and other countries.
The joint venture between China and Cuba, Biotech Pharma (BPL), has conducted research to expand the application of Nimotuzumab beyond the treatment of nasopharyngeal cancer. Mayda Mauri, the First Vice President of BioCubaFarma, highlighted BPL’s significant contribution to healthcare in both countries and its role in supplying Nimotuzumab during the COVID-19 pandemic, as well as ongoing studies on new indications for this monoclonal antibody.
Top headline:
Crónica Digital. (2023, 12 de junio). China aprueba uso de medicamento cubano para cáncer de páncreas.
Find out more:
Prensa Latina. (2023, 12 de junio). China aprueba uso de medicamento cubano para cáncer de páncreas.